Hormone Refractory Prostate Cancer Market

Hormone Refractory Prostate Cancer (HRPCA) or Castrate-Resistant Prostate Cancer (CRPC), a type of prostate cancer that typically recurs after having hormonal Therapy, is now under the spotlight in prostate cancer market. Due to the high unmet clinical need associated with limited survival periods, intensifying HRPCA prevalence and fast-emerging treatment modifications, the global HRPCA market is poised to witness an unprecedented growth.

Hormone Refractory Prostate Cancer Market contains market size and forecasts of Hormone Refractory Prostate Cancer (HRPCA) in Global, including the following market information:

• Global Hormone Refractory Prostate Cancer (HRPCA) Market Revenue, 2017-2022, 2023-2028, ($ millions)
• Global top five companies in 2021 (%)

The global Hormone Refractory Prostate Cancer (HRPCA) market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.

The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.

Cytotoxic Agents Segment to Reach $ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Hormone Refractory Prostate Cancer (HRPCA) include Astellas Inc, Sanofi S.A, Dendreon Corporation, Bayer AG and Johnson & Johnson, etc. In 2021, the global top five players have a share approximately % in terms of revenue.

We surveyed the Hormone Refractory Prostate Cancer (HRPCA) companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Hormone Refractory Prostate Cancer (HRPCA) Market, by Type, 2017-2022, 2023-2028 ($ millions)

Global Hormone Refractory Prostate Cancer (HRPCA) Market Segment Percentages, by Type, 2021 (%)

• Cytotoxic Agents
• Anti-Androgens
• Vaccines
• Radio-Pharmaceuticals

Global Hormone Refractory Prostate Cancer (HRPCA) Market, by Application, 2017-2022, 2023-2028 ($ millions)

Global Hormone Refractory Prostate Cancer (HRPCA) Market Segment Percentages, by Application, 2021 (%)

• Hospitals
• Ambulatory Surgical Centers
• Specialty Clinics
• Others

Global Hormone Refractory Prostate Cancer (HRPCA) Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)

Global Hormone Refractory Prostate Cancer (HRPCA) Market Segment Percentages, By Region and Country, 2021 (%)

• North America
• US
• Canada
• Mexico
• Europe
• Germany
• France
• U.K.
• Italy
• Russia
• Nordic Countries
• Benelux
• Rest of Europe
• Asia
• China
• Japan
• South Korea
• Southeast Asia
• India
• Rest of Asia
• South America
• Brazil
• Argentina
• Rest of South America
• Middle East & Africa
• Turkey
• Israel
• Saudi Arabia
• UAE
• Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

• Key companies Hormone Refractory Prostate Cancer (HRPCA) revenues in global market, 2017-2022 (estimated), ($ millions)
• Key companies Hormone Refractory Prostate Cancer (HRPCA) revenues share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

• Astellas Inc
• Sanofi S.A
• Dendreon Corporation, Bayer AG
• Johnson & Johnson